Evidence map›Paper›PMID 39501968›Full record

ReviewAdvanced healthcare materials2025

Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.

Priyanka Singh, Santosh Pandit, Sri Renukadevi Balusamy, Mukil Madhusudanan, Hina Singh, H Mohamed Amsath Haseef, Ivan Mijakovic

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Synthesis, Characterization, and Magnetic Properties of Fe(BIP)Pharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Priyanka SinghThe Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, DK-2800, Denmark.ORCID 0000-0001-7654-5339
Santosh PanditSystems and Synthetic Biology Division, Department of Life Sciences, Chalmers University of Technology, Gothenburg, SE-412 96, Sweden.ORCID 0000-0002-8357-758X
Sri Renukadevi BalusamyDepartment of Food Science and Biotechnology, Sejong University, Gwangjin-Gu, Seoul, 05006, Republic of Korea.
Mukil MadhusudananThe Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, DK-2800, Denmark.
Hina SinghDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, 92521, USA.
H Mohamed Amsath HaseefFaculty of Engineering Science, KU Leuven, Leuven, 3000, Belgium.
Ivan MijakovicThe Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kogens Lyngby, DK-2800, Denmark.

Funding

Danmarks Frie Forskningsfond 3164-00026ALundbeck Foundation R303-2018-3499NordForsk 105121Novo Nordisk Pharma NNF20CC0035580
6 · The paper itself

Abstract

Cancer remains one of the most challenging health issues globally, demanding innovative therapeutic approaches for effective treatment. Nanoparticles, particularly those composed of gold, silver, and iron oxide, have emerged as promising candidates for changing cancer therapy. This comprehensive review demonstrates the landscape of nanoparticle-based oncological interventions, focusing on the remarkable advancements and therapeutic potentials of gold, silver, and iron oxide nanoparticles. Gold nanoparticles have garnered significant attention for their exceptional biocompatibility, tunable surface chemistry, and distinctive optical properties, rendering them ideal candidates for various cancer diagnostic and therapeutic strategies. Silver nanoparticles, renowned for their antimicrobial properties, exhibit remarkable potential in cancer therapy through multiple mechanisms, including apoptosis induction, angiogenesis inhibition, and drug delivery enhancement. With their magnetic properties and biocompatibility, iron oxide nanoparticles offer unique cancer diagnosis and targeted therapy opportunities. This review critically examines the recent advancements in the synthesis, functionalization, and biomedical applications of these nanoparticles in cancer therapy. Moreover, the challenges are discussed, including toxicity concerns, immunogenicity, and translational barriers, and ongoing efforts to overcome these hurdles are highlighted. Finally, insights into the future directions of nanoparticle-based cancer therapy and regulatory considerations, are provided aiming to accelerate the translation of these promising technologies from bench to bedside.

Indexed as

Ferric CompoundsGoldMagnetic Iron Oxide NanoparticlesMetal NanoparticlesNeoplasmsSilverAnimalsHumansFerric Compoundsferric oxideGoldSilvercancer therapycombination therapydiagnosticdrug deliverygold nanoparticlesimaging, iron oxide nanoparticlesmetallic nanoparticlespersonalized medicinesilver nanoparticles

Identifiers

PMID39501968
PMCPMC11804848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.